Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravesical Gemcitabine and Docetaxel for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study (GEMDOCE-BU)

NCT07322263 is registered in ClinicalTrials.gov with Michael A. O'Donnell as lead sponsor.

NCT NCT07322263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07322263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravesical Gemcitabine and Docetaxel for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study (GEMDOCE-BU)
Lead sponsor
Michael A. O'Donnell
Phase
Phase 2
Overall status
Recruiting
Start date
April 10, 2026
Completion date
January 1, 2033
Enrollment
174 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bcg-refractory bladder cancer, bcg-unresponsive bladder cancer, bladder cancer, carcinoma in situ (cis), high-grade papillary bladder tumors, high-risk nmibc, micropapillary variant urothelial carcinoma (favorable subtype), non-muscle invasive bladder cancer (nmibc), t1 stage bladder cancer, ta stage bladder cancer, urothelial carcinoma